조용준

조용준 (chief executive) discloses dealings in 2 companies, chiefly 동구바이오제약 and 유비벨록스. Between 26 February 2021 and 8 October 2026, the trades on record add up to 44 filings.

In open-market terms, that means 6 purchases worth €2,759 on one side and 3 sales on the other. No amount is published for 8 filings, which the totals therefore leave out. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. 2026 to date brings 5 purchases and 2 sales.

Clusters matter here: 1 out of 6 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

Most recently, on 8 October 2026, the filings show a transaction in 동구바이오제약. The most recent open-market purchase was published on 7 July 2026, 103 days ago. Typically, a trade is published a median of 7 days after it takes place. That lag is the time during which only the insider knows about the trade. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.